These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

994 related items for PubMed ID: 18289825

  • 1. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients.
    Colombo PE, Mourregot A, Fabbro M, Gutowski M, Saint-Aubert B, Quenet F, Gourgou S, Rouanet P.
    Eur J Surg Oncol; 2009 Feb; 35(2):135-43. PubMed ID: 18289825
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY.
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
    Eisenkop SM, Friedman RL, Wang HJ.
    Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
    [Abstract] [Full Text] [Related]

  • 7. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
    Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A.
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY, Seo SS, Kang S, Lee KB, Lim SY, Choi HS, Park SY.
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
    Estes JM, Leath CA, Straughn JM, Rocconi RP, Kirby TO, Huh WK, Barnes MN.
    J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.
    Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P.
    Gynecol Oncol; 1998 Dec; 71(3):431-6. PubMed ID: 9887245
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.